FDA compounder NDC directory
Browse every current FDA compounder source row, including records that do not contain a usable NDC.
Compounder NDC directory#
Every current compounder source row is browsable, including records whose FDA source did not provide a usable product, package, or lookup NDC. Browse the unified current auxiliary catalog. · Browse the complete captured source and snapshot history.
| Establishment | FEI | Product NDC | Package NDC | Brand | Nonproprietary name | Active ingredients | Period | Normalization | Source date |
|---|---|---|---|---|---|---|---|---|---|
| "Compound Preferred, LLC(014579844)" | Benzocaine; Lidocaine Hydrochloride; Tetracaine Hydrochloride | .2 g/1 g; .06 g/1 g; .04 g/1 g | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Compound Preferred, LLC(014579844)" | Benzocaine; Lidocaine Hydrochloride; Tetracaine Hydrochloride | .2 g/1 g; .06 g/1 g; .04 g/1 g | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Compound Preferred, LLC(014579844)" | Phenylephrine Hydrochloride; Lidocaine Hydrochloride; Tetracaine Hydrochloride; Prilocaine Hydrochloride | 20 mg/1 g; 100 mg/1 g; 40 mg/1 g; 100 mg/1 g | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Compound Preferred, LLC(014579844)" | Bevacizumab | 1.25 mg/.05 mL | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Compound Preferred, LLC(014579844)" | Bevacizumab | 1.25 mg/.05 mL | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Compound Preferred, LLC(014579844)" | Bevacizumab | 1.25 mg/.05 mL | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Compound Preferred, LLC(014579844)" | Procaine Hydrochloride | 20 mg/1 mL | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Compound Preferred, LLC(014579844)" | Procaine Hydrochloride | 10 mg/1 mL | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Compound Preferred, LLC(014579844)" | Procaine Hydrochloride | 10 mg/1 mL | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Compound Preferred, LLC(014579844)" | Ranibizumab | .5 mg/.05 mL | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Compound Preferred, LLC(014579844)" | Brolucizumab | 6 mg/.05 mL | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Compound Preferred, LLC(014579844)" | Brolucizumab | 6 mg/.05 mL | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Compound Preferred, LLC(014579844)" | Squaric Acid Dibutyl Ester | 20 mg/1 mL | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Compound Preferred, LLC(014579844)" | Tetracaine Hydrochloride | 5 mg/1 g | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Compound Preferred, LLC(014579844)" | Tetracaine Hydrochloride | 40 mg/1 mL | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Compound Preferred, LLC(014579844)" | Tetracaine Hydrochloride; Epinephrine Bitartrate; Lidocaine Hydrochloride | 5 mg/1 g; .5 mg/1 g; .04 g/1 g | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Compound Preferred, LLC(014579844)" | Tetracaine Hydrochloride; Epinephrine Bitartrate; Lidocaine Hydrochloride | 5 mg/1 g; .5 mg/1 g; .04 g/1 g | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Compound Preferred, LLC(014579844)" | Tranexamic Acid | 50 mg/1 mL | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Compound Preferred, LLC(014579844)" | Dexpanthenol | 250 mg/1 mL | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Compound Preferred, LLC(014579844)" | Dexpanthenol | 250 mg/1 mL | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Compound Preferred, LLC(014579844)" | Dyclonine Hydrochloride; Lidocaine Hydrochloride | 10 mg/1 mL; 10 mg/1 mL | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Compound Preferred, LLC(014579844)" | Dyclonine Hydrochloride; Lidocaine Hydrochloride | 10 mg/1 mL; 10 mg/1 mL | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Compound Preferred, LLC(014579844)" | Aflibercept | 2 mg/.05 mL | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Compound Preferred, LLC(014579844)" | Lidocaine Hydrochloride; Phenylephrine Hydrochloride | 40 mg/1 mL; 40 mg/1 mL | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Compound Preferred, LLC(014579844)" | Lidocaine Hydrochloride; Tetracaine Hydrochloride; Benzocaine | .06 g/1 g; .04 g/1 g; .2 g/1 g | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Compound Preferred, LLC(014579844)" | Lidocaine Hydrochloride; Tetracaine Hydrochloride; Phenylephrine Hydrochloride | 200 mg/1 g; 40 mg/1 g; 20 mg/1 g | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Compound Preferred, LLC(014579844)" | Lidocaine Hydrochloride; Tetracaine Hydrochloride; Phenylephrine Hydrochloride | 200 mg/1 g; 40 mg/1 g; 20 mg/1 g | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Compound Preferred, LLC(014579844)" | Lidocaine Hydrochloride; Tetracaine Hydrochloride; Prilocaine Hydrochloride | 100 mg/1 g; 40 mg/1 g; 100 mg/1 g | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Compound Preferred, LLC(014579844)" | Lidocaine Hydrochloride; Tetracaine Hydrochloride; Prilocaine Hydrochloride | 100 mg/1 g; 40 mg/1 g; 100 mg/1 g | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Compound Preferred, LLC(014579844)" | Lidocaine Hydrochloride; Tetracaine Hydrochloride; Prilocaine Hydrochloride | 100 mg/1 g; 40 mg/1 g; 100 mg/1 g | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Compound Preferred, LLC(014579844)" | Lidocaine Hydrochloride; Tetracaine Hydrochloride; Prilocaine Hydrochloride | 100 mg/1 g; 40 mg/1 g; 100 mg/1 g | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Compound Preferred, LLC(014579844)" | Lidocaine; Tetracaine | 40 mg/1 g; 100 mg/1 g | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Compound Preferred, LLC(014579844)" | Lidocaine; Tetracaine | .23 g/1 g; .07 g/1 g | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Compound Preferred, LLC(014579844)" | Lidocaine; Tetracaine | .23 g/1 g; .07 g/1 g | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Denver Solutions, LLC dba Leiters Health(080586798)" | Midazolam Hydrochloride | 5 mg/1 mL | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Denver Solutions, LLC dba Leiters Health(080586798)" | Morphine Sulfate | 5 mg/1 mL | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Denver Solutions, LLC dba Leiters Health(080586798)" | Moxifloxacin Hydrochloride | 5 mg/1 mL | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Denver Solutions, LLC dba Leiters Health(080586798)" | Moxifloxacin Hydrochloride | 1 mg/1 mL | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Denver Solutions, LLC dba Leiters Health(080586798)" | Atropine Sulfate | .4 mg/1 mL | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Denver Solutions, LLC dba Leiters Health(080586798)" | Neostigmine Methylsulfate | 1 mg/1 mL | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Denver Solutions, LLC dba Leiters Health(080586798)" | Neostigmine Methylsulfate | 1 mg/1 mL | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Denver Solutions, LLC dba Leiters Health(080586798)" | Neostigmine Methylsulfate | 1 mg/1 mL | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Denver Solutions, LLC dba Leiters Health(080586798)" | Neostigmine Methylsulfate | 1 mg/1 mL | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Denver Solutions, LLC dba Leiters Health(080586798)" | Phenylephrine Hydrochloride | 100 ug/1 mL | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Denver Solutions, LLC dba Leiters Health(080586798)" | Phenylephrine Hydrochloride | 100 ug/1 mL | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Denver Solutions, LLC dba Leiters Health(080586798)" | Bevacizumab | 25 mg/1 mL | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Denver Solutions, LLC dba Leiters Health(080586798)" | Bevacizumab | 25 mg/1 mL | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Denver Solutions, LLC dba Leiters Health(080586798)" | Phenylephrine Hydrochloride; Cyclopentolate Hydrochloride; Tropicamide | 25 mg/1 mL; 10 mg/1 mL; 10 mg/1 mL | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Denver Solutions, LLC dba Leiters Health(080586798)" | Bevacizumab | 25 mg/1 mL | 2021-1 | source_no_ndc | 2026-11-12 | ||||
| "Denver Solutions, LLC dba Leiters Health(080586798)" | Phenylephrine Hydrochloride; Tropicamide; Cyclopentolate Hydrochloride | 25 mg/1 mL; 10 mg/1 mL; 10 mg/1 mL | 2021-1 | source_no_ndc | 2026-11-12 |